These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16671156)

  • 1. Warning on Strattera for attention-deficit hyperactivity disorder.
    FDA Consum; 2005; 39(6):4. PubMed ID: 16671156
    [No Abstract]   [Full Text] [Related]  

  • 2. [Atomoxetine--Strattera. Oral preparation].
    Duh PD; Macken E
    J Pharm Belg; 2006; 61(4):117-20. PubMed ID: 17263193
    [No Abstract]   [Full Text] [Related]  

  • 3. Suicidal ideation among children taking atomoxetine (Strattera).
    Wooltorton E
    CMAJ; 2005 Dec; 173(12):1447. PubMed ID: 16330634
    [No Abstract]   [Full Text] [Related]  

  • 4. Does atomoxetine increase the risk of aggression and hostility in children with attention deficit hyperactivity disorder?
    Banerjee S; Ayyash HF
    Arch Dis Child Educ Pract Ed; 2008 Aug; 93(4):131-2. PubMed ID: 18644903
    [No Abstract]   [Full Text] [Related]  

  • 5. Atomoxetine-induced hyponatremia.
    Singh T
    Aust N Z J Psychiatry; 2007 May; 41(5):458. PubMed ID: 17464740
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute suicidality after commencing atomoxetine.
    Paxton GA; Cranswick NE
    J Paediatr Child Health; 2008 Oct; 44(10):596-8. PubMed ID: 19012633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased blood pressure and atomoxetine.
    Dworkin N
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):510. PubMed ID: 15908831
    [No Abstract]   [Full Text] [Related]  

  • 8. Atomoxetine-induced electrocardiogram changes.
    Rajesh AS; Bates G; Wright JG
    Arch Dis Child; 2006 Dec; 91(12):1023-4. PubMed ID: 17119076
    [No Abstract]   [Full Text] [Related]  

  • 9. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 11. First case of sialolithiasis associated with atomoxetine.
    Jerome L; Gardner D; Kutcher SP
    J Clin Psychopharmacol; 2007 Feb; 27(1):111-2. PubMed ID: 17224735
    [No Abstract]   [Full Text] [Related]  

  • 12. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 13. What is the significance of the new warnings about suicide risk with Strattera?
    Miller MC
    Harv Ment Health Lett; 2005 Dec; 22(6):8. PubMed ID: 16437773
    [No Abstract]   [Full Text] [Related]  

  • 14. Atomoxetine-induced mania-like symptoms in an adolescent patient.
    Bahali K; Uneri OS; Ipek H
    Actas Esp Psiquiatr; 2013; 41(2):137-8. PubMed ID: 23592075
    [No Abstract]   [Full Text] [Related]  

  • 15. Atomoxetine-induced mania with auditory hallucination in an 8-year-old boy with attention-deficit/hyperactivity disorder and tic disorder.
    Liu CC; Lan CC; Chen YS
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):466-7. PubMed ID: 25020072
    [No Abstract]   [Full Text] [Related]  

  • 16. [Raynaud phenomenon as adverse effect of ADHD treatment].
    Lakartidningen; 2008 Dec 10-16; 105(50):3662-3. PubMed ID: 19177933
    [No Abstract]   [Full Text] [Related]  

  • 17. Persistent camptocormia associated with atomoxetine in a child with attention-deficit/hyperactivity disorder.
    Bhattacharya A; Praharaj SK; Sinha VK
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):596-7. PubMed ID: 25469421
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    ; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.